Home › Cancro dell'esofago › Pennsylvania › Pittsburgh
Studi clinici su Cancro dell'esofago a Pittsburgh, PA
15 studi su Cancro dell'esofago cercano partecipanti presso sedi a Pittsburgh e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
In reclutamentoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
In reclutamento
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
In reclutamentoFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
In reclutamentoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
In reclutamentoFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
In reclutamentoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
In reclutamentoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
In reclutamentoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
In reclutamento
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
In reclutamentoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
In reclutamentoStudio osservazionale
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
In reclutamentoStudio osservazionale
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
In reclutamentoStudio osservazionale
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
In reclutamentoFase 1
- AHN West Penn Hospital, Pittsburgh
Studi su Cancro dell'esofago in altre città
- Houston, TX36 studi
- Boston, MA23 studi
- New York City, NY22 studi
- Nashville, TN19 studi
- St. Louis, MO17 studi
- Los Angeles, CA15 studi
- Baldwin Park, CA14 studi
- Grand Rapids, MI14 studi
- Philadelphia, PA13 studi
- San Antonio, TX12 studi
- Rochester, MN11 studi
- Arlington, VA11 studi
Altri studi a Pittsburgh
- Cancro del polmone non a piccole cellule48 studi
- Cancro (tutti i tipi)41 studi
- Cancro al seno39 studi
- Cancro colorettale32 studi
- Cancro metastatico31 studi
- Melanoma31 studi
- Cancro ovarico30 studi
- Cancro dell'endometrio23 studi
- Cancro alla prostata23 studi
- Cancro ai polmoni23 studi
- Carcinoma a cellule squamose della testa e del collo22 studi
- Ictus22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.